DYN
Dyne Therapeutics, Inc.
- Latest sale
- $25k
- Sep 8 · Unusual
- Form 4 sales
- 192
- On record
- Form 144 notices
- 28
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineAug 13 2026
Sold 4,986 shares at $26.28 ($131k)
Cox John, CEO & President
10b5-1 planSold 1.4% of holdings ($9.7M position)363,165 shares left1.8x usual sizeFiling
- 2 Form 4 saleRoutineAug 13 same day
Sold 1,797 shares at $26.28 ($47k)
Lucera Erick, Chief Financial Officer
10b5-1 planSold 1.5% of holdings ($3.2M position)119,766 shares left0.8x usual sizeFiling
- 3 Form 4 saleRoutineAug 13 same day
Sold 1,556 shares at $26.28 ($41k)
Kerr Douglas, Chief Medical Officer
10b5-1 planSold 0.9% of holdings ($4.4M position)167,599 shares left1.2x usual sizeFiling
- 4 Form 4 saleRoutineAug 13 same day
Sold 226 shares at $26.28 ($6k)
Friedl-Naderer Johanna, Chief Commercial Officer
10b5-1 planSold 0.1% of holdings ($4.1M position)153,982 shares left1.5x usual sizeFiling
- 5 Form 4 saleUnusualAug 14 +1 day
Sold 2.6M shares at $25.20 ($65.2M)
Rhodes Jason P, Director
10b5-1 planSold 85.8% of holdings ($76M position)428,946 shares left7.9x usual sizeFiling
- 6 Form 4 saleRoutineSep 8 +25 days
Sold 5,658 shares at $18.88 ($107k)
Cox John, CEO & President
10b5-1 planSold 1.6% of holdings ($6.9M position)357,507 shares left1.9x usual sizeFiling
- 7 Form 4 saleUnusualSep 8 same day
Sold 5,035 shares at $22.95 ($116k)
Kerr Douglas, Chief Medical Officer
10b5-1 planSold 3% of holdings ($3.8M position)162,564 shares left3.8x usual sizeFiling
- 8 Form 4 saleUnusualSep 8 same day
Sold 1,085 shares at $23.42 ($25k)
Friedl-Naderer Johanna, Chief Commercial Officer
10b5-1 planSold 0.7% of holdings ($3.6M position)152,897 shares left7.4x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (220)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 1,085 | $25k | 0.7% | Unusual | SEC |
| Sep 8, 2026 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 5,035 | $116k | 3.0% | Unusual | SEC |
| Sep 8, 2026 | Cox John | CEO & President | Form 4 sale | 5,658 | $107k | 1.6% | Routine | SEC |
| Aug 14, 2026 | Rhodes Jason P | Director | Form 4 sale | 2.6M | $65.2M | 85.8% | Unusual | SEC |
| Aug 13, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 226 | $6k | 0.1% | Routine | SEC |
| Aug 13, 2026 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 1,556 | $41k | 0.9% | Routine | SEC |
| Aug 13, 2026 | Lucera Erick | Chief Financial Officer | Form 4 sale | 1,797 | $47k | 1.5% | Routine | SEC |
| Aug 13, 2026 | Cox John | CEO & President | Form 4 sale | 4,986 | $131k | 1.4% | Routine | SEC |
| Jul 27, 2026 | Kersten Dirk | Director | Form 4 sale | 261,460 | $6.7M | 6.8% | Routine | SEC |
| Jul 7, 2026 | Rhodes Jason P | Director | Form 4 sale | 777,451 | $17.9M | 99.6% | Routine | SEC |
| Jun 29, 2026 | Rhodes Jason P | Director | Form 4 sale | 504,695 | $10.7M | 34.1% | Routine | SEC |
| Jun 25, 2026 | Rhodes Jason P | Director | Form 4 sale | 267,760 | $5.6M | 19.9% | Routine | SEC |
| Jun 25, 2026 | Lucera Erick | Chief Financial Officer | Form 4 sale | 2,362 | $48k | 1.9% | No plan | SEC |
| Jun 23, 2026 | Kersten Dirk | Director | Form 4 sale | 263,962 | $5.5M | 6.4% | Routine | SEC |
| Jun 18, 2026 | Kersten Dirk | Director | Form 4 sale | 84,355 | $1.7M | 2.0% | Routine | SEC |
| Jun 16, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 145 | $3k | 0.1% | Routine | SEC |
| Jun 16, 2026 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 887 | $16k | 0.5% | Routine | SEC |
| Jun 16, 2026 | Cox John | CEO & President | Form 4 sale | 2,683 | $49k | 0.7% | Routine | SEC |
| May 13, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 228 | $4k | 0.1% | Routine | SEC |
| May 13, 2026 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 1,564 | $29k | 0.9% | Routine | SEC |
| May 13, 2026 | Lucera Erick | Chief Financial Officer | Form 4 sale | 1,448 | $27k | 1.2% | Routine | SEC |
| May 13, 2026 | Cox John | CEO & President | Form 4 sale | 3,311 | $61k | 0.9% | Routine | SEC |
| May 6, 2026 | Rhodes Jason P | Director | Form 4 sale | 106,723 | $1.9M | 8.6% | Routine | SEC |
| Apr 28, 2026 | Rhodes Jason P | Director | Form 4 sale | 227,337 | $4.2M | 16.4% | Routine | SEC |
| Apr 27, 2026 | Rhodes Jason P | Director | Form 4 sale | 384,549 | $7.1M | 24.2% | Routine | SEC |
| Apr 22, 2026 | Kersten Dirk | Director | Form 4 sale | 10,952 | $219k | 0.3% | Routine | SEC |
| Apr 22, 2026 | Rhodes Jason P | Director | Form 4 sale | 834,302 | $16.5M | 39.4% | Routine | SEC |
| Apr 20, 2026 | Kersten Dirk | Director | Form 4 sale | 337,248 | $6.8M | 7.4% | Routine | SEC |
| Apr 16, 2026 | Kersten Dirk | Director | Form 4 sale | 99,613 | $2M | 2.1% | Routine | SEC |
| Apr 1, 2026 | Lucera Erick | Chief Financial Officer | Form 4 sale | 5,727 | $107k | 4.4% | Routine | SEC |
| Mar 11, 2026 | Kersten Dirk | Director | Form 4 sale | 129,672 | $2.5M | 2.7% | Routine | SEC |
| Mar 10, 2026 | Kersten Dirk | Director | Form 4 sale | 688,788 | $13.2M | 12.6% | Unusual | SEC |
| Mar 5, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 148 | $2k | 0.1% | Routine | SEC |
| Mar 5, 2026 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 904 | $13k | 0.5% | Routine | SEC |
| Mar 5, 2026 | Cox John | CEO & President | Form 4 sale | 2,732 | $41k | 0.7% | Routine | SEC |
| Dec 5, 2025 | Cox John | CEO & President | Form 4 sale | 2,662 | $55k | 1.3% | Routine | SEC |
| Dec 5, 2025 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 880 | $18k | 1.0% | Routine | SEC |
| Dec 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 144 | $3k | 0.2% | Routine | SEC |
| Sep 5, 2025 | Cox John | CEO & President | Form 4 sale | 2,640 | $35k | 1.3% | Routine | SEC |
| Sep 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 1,038 | $14k | 1.1% | Routine | SEC |
| Sep 5, 2025 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 4,425 | $59k | 4.8% | Routine | SEC |
| Jun 5, 2025 | Cox John | CEO & President | Form 4 sale | 4,060 | $54k | 2.8% | Routine | SEC |
| Jun 5, 2025 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 1,342 | $18k | 1.4% | Routine | SEC |
| Jun 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 146 | $2k | 0.2% | Routine | SEC |
| Mar 13, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Form 4 sale | 143 | $2k | 0.1% | Routine | SEC |
| Mar 11, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 1,343 | $15k | 1.1% | Routine | SEC |
| Mar 11, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,153 | $25k | 1.1% | Routine | SEC |
| Mar 5, 2025 | Kerr Douglas | Chief Medical Officer | Form 4 sale | 1,343 | $16k | 1.4% | Routine | SEC |
| Mar 5, 2025 | Cox John | CEO & President | Form 4 sale | 4,061 | $48k | 2.7% | Routine | SEC |
| Mar 5, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 917 | $11k | 0.7% | Routine | SEC |
| Mar 5, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 1,094 | $13k | 0.5% | Routine | SEC |
| Feb 18, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,598 | $36k | 1.3% | Routine | SEC |
| Feb 18, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 2,488 | $35k | 2.0% | Routine | SEC |
| Dec 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,334 | $66k | 1.1% | Routine | SEC |
| Dec 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 1,455 | $41k | 1.1% | Routine | SEC |
| Dec 11, 2024 | High Susanna Gatti | Officer | Form 144 notice | 5,270 | $149k | Notice | SEC | |
| Dec 11, 2024 | Beskrovnaya Oxana | Officer | Form 144 notice | 2,334 | $66k | Notice | SEC | |
| Dec 11, 2024 | Scalzo Richard William | Officer | Form 144 notice | 1,455 | $41k | Notice | SEC | |
| Dec 9, 2024 | Kersten Dirk | Director | Form 4 sale | 136,112 | $4M | 2.5% | No plan | SEC |
| Dec 5, 2024 | Kersten Dirk | Director | Form 4 sale | 138,845 | $4.1M | 2.4% | No plan | SEC |
| Dec 3, 2024 | Kersten Dirk | Director | Form 4 sale | 110,933 | $3.3M | 1.9% | No plan | SEC |
| Nov 25, 2024 | McNeill Jonathan | Officer | Form 144 notice | 19,987 | $593k | Notice | SEC | |
| Nov 22, 2024 | Forbion Capital Fund IV Cooperatief U.A. | Affiliate | Form 144 notice | 62,301 | $1.9M | Notice | SEC | |
| Nov 18, 2024 | Incerti Carlo | Director | Form 4 sale | 16,500 | $474k | 100.0% | Unusual | SEC |
| Nov 18, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 2,735 | $77k | 2.8% | Routine | SEC |
| Nov 18, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,856 | $81k | 2.0% | Routine | SEC |
| Nov 14, 2024 | Rhodes Jason P | Director | Form 4 sale | 782 | $26k | 0.1% | No plan | SEC |
| Nov 14, 2024 | Kersten Dirk | Director | Form 4 sale | 19,732 | $674k | 0.3% | Routine | SEC |
| Oct 21, 2024 | Kersten Dirk | Director | Form 4 sale | 13,535 | $476k | 15.6% | Routine | SEC |
| Oct 17, 2024 | Kersten Dirk | Director | Form 4 sale | 36,684 | $1.3M | 29.7% | Routine | SEC |
| Oct 3, 2024 | Kersten Dirk | Director | Form 4 sale | 5,441 | $191k | 4.2% | Routine | SEC |
| Oct 2, 2024 | Kersten Dirk | Director | Form 4 sale | 29,941 | $1.1M | 18.9% | Routine | SEC |
| Sep 30, 2024 | Kersten Dirk | Director | Form 4 sale | 30,974 | $1.1M | 16.3% | Routine | SEC |
| Sep 26, 2024 | Kersten Dirk | Director | Form 4 sale | 3,617 | $127k | 1.9% | Routine | SEC |
| Sep 23, 2024 | Kersten Dirk | Director | Form 4 sale | 120,242 | $4.3M | 38.4% | Routine | SEC |
| Sep 19, 2024 | Kersten Dirk | Director | Form 4 sale | 80,293 | $2.9M | 20.4% | Routine | SEC |
| Sep 18, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 8,976 | $309k | 6.4% | Unusual | SEC |
| Sep 18, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 1,390 | $48k | 1.4% | Routine | SEC |
| Sep 18, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,339 | $81k | 1.6% | Routine | SEC |
| Sep 17, 2024 | Kersten Dirk | Director | Form 4 sale | 4,592 | $161k | 1.2% | Routine | SEC |
| Sep 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,161 | $69k | 1.5% | Routine | SEC |
| Sep 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 1,468 | $47k | 1.4% | Routine | SEC |
| Sep 11, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 5,270 | $168k | 3.6% | Routine | SEC |
| Sep 6, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 126,074 | $4.1M | 55.4% | Unusual | SEC |
| Sep 5, 2024 | Kersten Dirk | Director | Form 4 sale | 1,577 | $55k | 0.4% | Routine | SEC |
| Aug 30, 2024 | Kersten Dirk | Director | Form 4 sale | 31,300 | $1.4M | 7.3% | Routine | SEC |
| Aug 29, 2024 | Kersten Dirk | Director | Form 4 sale | 134,261 | $6M | 23.7% | Routine | SEC |
| Aug 27, 2024 | Kersten Dirk | Director | Form 4 sale | 154,900 | $7M | 21.5% | Routine | SEC |
| Aug 23, 2024 | Kersten Dirk | Director | Form 4 sale | 180,409 | $8.3M | 20.0% | Routine | SEC |
| Aug 21, 2024 | Kersten Dirk | Director | Form 4 sale | 222,603 | $10.4M | 19.8% | Routine | SEC |
| Aug 19, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 2,752 | $124k | 2.4% | Routine | SEC |
| Aug 19, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 2,705 | $122k | 2.0% | Routine | SEC |
| Aug 19, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 2,321 | $105k | 1.6% | Routine | SEC |
| Aug 19, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 2,910 | $131k | 2.0% | Routine | SEC |
| Aug 19, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,636 | $119k | 1.8% | Routine | SEC |
| Aug 19, 2024 | Kersten Dirk | Director | Form 4 sale | 248,675 | $11.3M | 18.1% | Routine | SEC |
| Aug 15, 2024 | Kersten Dirk | Director | Form 4 sale | 281,541 | $12.6M | 17.0% | Routine | SEC |
| Aug 13, 2024 | Kersten Dirk | Director | Form 4 sale | 212,477 | $9.1M | 11.4% | Routine | SEC |
| Aug 9, 2024 | Kersten Dirk | Director | Form 4 sale | 183,834 | $7.9M | 2.9% | Routine | SEC |
| Jun 24, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 39,950 | $1.4M | 21.2% | Unusual | SEC |
| Jun 12, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 40,000 | $1.3M | 21.2% | Unusual | SEC |
| Jun 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,136 | $67k | 1.4% | No plan | SEC |
| Jun 11, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 2,636 | $82k | 1.8% | Routine | SEC |
| Jun 11, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 85,270 | $2.6M | 36.4% | Unusual | SEC |
| Jun 11, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 1,823 | $57k | 1.3% | No plan | SEC |
| Jun 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 2,921 | $90k | 2.5% | Routine | SEC |
| May 20, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 30,426 | $1M | 16.9% | Unusual | SEC |
| May 16, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,705 | $76k | 1.8% | Routine | SEC |
| May 16, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 2,381 | $67k | 1.6% | Routine | SEC |
| May 16, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 2,738 | $77k | 1.7% | Routine | SEC |
| May 16, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 2,588 | $73k | 2.2% | Routine | SEC |
| May 16, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 2,774 | $78k | 2.0% | Routine | SEC |
| Mar 12, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 2,615 | $67k | 1.7% | Routine | SEC |
| Mar 11, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 29,491 | $784k | 15.8% | Unusual | SEC |
| Mar 11, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 109,601 | $2.9M | 44.0% | Unusual | SEC |
| Mar 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 88,924 | $2.3M | 42.7% | Unusual | SEC |
| Mar 11, 2024 | Brumm Joshua T | CEO & President | Form 4 sale | 429,730 | $11.1M | 44.4% | Unusual | SEC |
| Mar 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,081 | $53k | 1.3% | Routine | SEC |
| Mar 7, 2024 | Brumm Joshua T | CEO & President | Form 4 sale | 9,086 | $235k | 1.6% | Routine | SEC |
| Mar 7, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 2,373 | $61k | 1.5% | Routine | SEC |
| Mar 7, 2024 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 1,591 | $41k | 0.8% | Routine | SEC |
| Mar 7, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 9,921 | $257k | 6.1% | Unusual | SEC |
| Mar 7, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 2,434 | $63k | 1.7% | Routine | SEC |
| Mar 7, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 2,273 | $59k | 1.8% | Routine | SEC |
| Mar 1, 2024 | Rhodes Jason P | Director | Form 4 sale | 46,534 | $1.4M | 5.2% | Routine | SEC |
| Mar 1, 2024 | Atlas Venture Associates Opportunity II, LP | 10% owner | Form 4 sale | 46,534 | $1.4M | 3.1% | Routine | SEC |
| Mar 1, 2024 | Brumm Joshua T | CEO & President | Form 4 sale | 100,000 | $2.9M | 15.1% | Unusual | SEC |
| Mar 1, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 28,528 | $812k | 16.6% | Unusual | SEC |
| Mar 1, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 12,740 | $357k | 9.3% | Unusual | SEC |
| Feb 28, 2024 | Rhodes Jason P | Director | Form 4 sale | 807,838 | $19.6M | 48.3% | Routine | SEC |
| Feb 28, 2024 | Atlas Venture Associates XI, L.P. | 10% owner | Form 4 sale | 807,838 | $19.6M | 12.4% | Routine | SEC |
| Feb 28, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 407 | $10k | 0.2% | Routine | SEC |
| Feb 23, 2024 | Rhodes Jason P | Director | Form 4 sale | 500,789 | $11.3M | 35.2% | Routine | SEC |
| Feb 23, 2024 | Atlas Venture Associates XI, LLC | 10% owner | Form 4 sale | 500,789 | $11.3M | 7.3% | Routine | SEC |
| Feb 20, 2024 | Rhodes Jason P | Director | Form 4 sale | 510,152 | $11.9M | 7.0% | Routine | SEC |
| Feb 20, 2024 | Atlas Venture Associates XI, L.P. | 10% owner | Form 4 sale | 510,152 | $11.9M | 7.0% | Routine | SEC |
| Feb 12, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 5,493 | $138k | 3.3% | Unusual | SEC |
| Jan 26, 2024 | Scalzo Richard William | Officer | Form 144 notice | 13,000 | $316k | Notice | SEC | |
| Jan 26, 2024 | McNeill Jonathan | Officer | Form 144 notice | 20,000 | $491k | Notice | SEC | |
| Jan 26, 2024 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 100 | $3k | 0.1% | Routine | SEC |
| Jan 26, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 20,000 | $491k | 12.2% | Unusual | SEC |
| Jan 26, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 13,000 | $316k | 9.5% | Unusual | SEC |
| Jan 4, 2024 | Brumm Joshua T | Officer | Form 144 notice | 218,536 | $4M | Notice | SEC | |
| Jan 4, 2024 | Beskrovnaya Oxana | Officer | Form 144 notice | 42,453 | $770k | Notice | SEC | |
| Jan 4, 2024 | McNeill Jonathan | Officer | Form 144 notice | 2,009 | $36k | Notice | SEC | |
| Jan 4, 2024 | Brumm Joshua T | CEO & President | Form 4 sale | 269,719 | $5M | 31.6% | Unusual | SEC |
| Jan 4, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 87,779 | $1.6M | 35.9% | Unusual | SEC |
| Jan 4, 2024 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 31,900 | $529k | 18.2% | Unusual | SEC |
| Jan 3, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 4 sale | 13,000 | $245k | 9.5% | Unusual | SEC |
| Jan 3, 2024 | McNeill Jonathan | Officer | Form 144 notice | 17,991 | $337k | Notice | SEC | |
| Jan 3, 2024 | Scalzo Richard William | Officer | Form 144 notice | 13,000 | $245k | Notice | SEC | |
| Jan 3, 2024 | Brumm Joshua T | Officer | Form 144 notice | 51,183 | $987k | Notice | SEC | |
| Jan 3, 2024 | Beskrovnaya Oxana | Officer | Form 144 notice | 45,326 | $860k | Notice | SEC | |
| Dec 29, 2023 | McNeill Jonathan | Officer | Form 144 notice | 11,900 | $158k | Notice | SEC | |
| Dec 14, 2023 | Scalzo Richard William | Officer | Form 144 notice | 2,376 | $29k | Notice | SEC | |
| Dec 14, 2023 | Scalzo Richard William | Officer | Form 4 sale | 2,376 | $29k | 1.9% | Routine | SEC |
| Dec 12, 2023 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 2,666 | $28k | 1.6% | Routine | SEC |
| Dec 11, 2023 | Scalzo Richard William | Officer | Form 4 sale | 1,380 | $15k | 1.1% | No plan | SEC |
| Dec 11, 2023 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 1,245 | $13k | 0.8% | No plan | SEC |
| Dec 11, 2023 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 1,616 | $17k | 0.9% | No plan | SEC |
| Dec 11, 2023 | Brumm Joshua T | Officer, Director | Form 4 sale | 7,585 | $81k | 1.3% | No plan | SEC |
| Dec 11, 2023 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 1,467 | $16k | 0.8% | No plan | SEC |
| Dec 11, 2023 | Scalzo Richard William | Officer | Form 144 notice | 1,380 | $15k | Notice | SEC | |
| Dec 11, 2023 | High Susanna Gatti | Officer | Form 144 notice | 1,616 | $17k | Notice | SEC | |
| Dec 11, 2023 | Brumm Joshua T | Officer | Form 144 notice | 7,585 | $81k | Notice | SEC | |
| Dec 6, 2023 | Scalzo Richard William | Officer | Form 144 notice | 1,872 | $22k | Notice | SEC | |
| Dec 6, 2023 | Scalzo Richard William | Officer | Form 4 sale | 2,553 | $31k | 2.0% | Routine | SEC |
| Nov 2, 2023 | High Susanna Gatti | Chief Operating Officer | Form 144 notice | 9,939 | $74k | Notice | SEC | |
| Nov 2, 2023 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 9,939 | $74k | 9.5% | Unusual | SEC |
| Sep 18, 2023 | Scalzo Richard William | Officer | Form 4 sale | 1,290 | $12k | 3.1% | No plan | SEC |
| Sep 18, 2023 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 1,261 | $12k | 2.0% | No plan | SEC |
| Sep 18, 2023 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 2,672 | $25k | 2.5% | No plan | SEC |
| Sep 18, 2023 | Brumm Joshua T | Officer, Director | Form 4 sale | 12,032 | $113k | 4.9% | No plan | SEC |
| Sep 18, 2023 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 1,436 | $14k | 1.7% | No plan | SEC |
| Sep 18, 2023 | Brumm Joshua T | CEO and President | Form 144 notice | 12,032 | $113k | Notice | SEC | |
| Sep 12, 2023 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 1,707 | $18k | 1.9% | No plan | SEC |
| Sep 12, 2023 | Scalzo Richard William | Officer | Form 4 sale | 1,397 | $15k | 3.2% | No plan | SEC |
| Sep 12, 2023 | McNeill Jonathan | Chief Business Officer | Form 4 sale | 1,266 | $13k | 2.0% | Routine | SEC |
| Sep 12, 2023 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 1,635 | $17k | 1.5% | No plan | SEC |
| Sep 12, 2023 | Brumm Joshua T | Officer, Director | Form 4 sale | 7,672 | $80k | 3.0% | No plan | SEC |
| Sep 12, 2023 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 1,484 | $15k | 1.7% | No plan | SEC |
| Sep 12, 2023 | Brumm Joshua T | CEO and President | Form 144 notice | 7,672 | $80k | Notice | SEC | |
| Jun 15, 2023 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 144 notice | 10,000 | $120k | Notice | SEC | |
| Jun 15, 2023 | Scalzo Richard William | Officer | Form 4 sale | 51,390 | $653k | 54.2% | Unusual | SEC |
| Jun 13, 2023 | McNeill Jonathan | Officer | Form 4 sale | 2,259 | $29k | 3.5% | Routine | SEC |
| Jun 13, 2023 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 1,625 | $20k | 1.5% | No plan | SEC |
| Jun 13, 2023 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 1,698 | $21k | 1.8% | No plan | SEC |
| Jun 13, 2023 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 1,475 | $18k | 1.7% | No plan | SEC |
| Jun 13, 2023 | Scalzo Richard William | SVP, Head of Finance & Admin. | Form 144 notice | 40,000 | $515k | Notice | SEC | |
| Jun 12, 2023 | Brumm Joshua T | CEO and President | Form 144 notice | 187,748 | $2.4M | Notice | SEC | |
| Jun 12, 2023 | Brumm Joshua T | Officer, Director | Form 4 sale | 325,330 | $4.2M | 56.2% | Unusual | SEC |
| Jun 9, 2023 | Brumm Joshua T | CEO and President | Form 144 notice | 76,582 | $1M | Notice | SEC | |
| Jun 8, 2023 | Brumm Joshua T | CEO and President | Form 144 notice | 61,000 | $807k | Notice | SEC | |
| Mar 14, 2023 | Scalzo Richard William | Officer | Form 4 sale | 1,311 | $17k | 2.3% | Unusual | SEC |
| Mar 14, 2023 | McNeill Jonathan | Officer | Form 4 sale | 2,209 | $29k | 3.3% | Plan not stated | SEC |
| Mar 14, 2023 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 1,559 | $21k | 1.4% | Plan not stated | SEC |
| Mar 14, 2023 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 7,441 | $99k | 7.4% | Unusual | SEC |
| Mar 14, 2023 | Brumm Joshua T | Officer, Director | Form 4 sale | 7,318 | $98k | 2.2% | Plan not stated | SEC |
| Mar 14, 2023 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 1,416 | $19k | 1.6% | Plan not stated | SEC |
| Jan 18, 2023 | McNeill Jonathan | Officer | Form 4 sale | 10,000 | $140k | 12.9% | Unusual | SEC |
| Jan 9, 2023 | McNeill Jonathan | Officer | Form 4 sale | 30,150 | $349k | 30.8% | Unusual | SEC |
| Dec 12, 2022 | Scalzo Richard William | Officer | Form 4 sale | 312 | $3k | 0.6% | Plan not stated | SEC |
| Dec 12, 2022 | McNeill Jonathan | Officer | Form 4 sale | 472 | $5k | 0.5% | Plan not stated | SEC |
| Dec 12, 2022 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 751 | $8k | 0.7% | Plan not stated | SEC |
| Dec 12, 2022 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 628 | $7k | 0.6% | Plan not stated | SEC |
| Dec 12, 2022 | Brumm Joshua T | Officer, Director | Form 4 sale | 3,322 | $36k | 1.0% | Plan not stated | SEC |
| Dec 12, 2022 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 680 | $7k | 0.7% | Plan not stated | SEC |
| Oct 10, 2022 | Brumm Joshua T | Officer, Director | Form 4 sale | 210,000 | $2.6M | 50.6% | Unusual | SEC |
| Mar 11, 2022 | Scalzo Richard William | Officer | Form 4 sale | 308 | $3k | 1.1% | Plan not stated | SEC |
| Mar 11, 2022 | McNeill Jonathan | Officer | Form 4 sale | 481 | $4k | 0.8% | Plan not stated | SEC |
| Mar 11, 2022 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 765 | $7k | 1.0% | Plan not stated | SEC |
| Mar 11, 2022 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 640 | $6k | 1.0% | Plan not stated | SEC |
| Mar 11, 2022 | Brumm Joshua T | Officer, Director | Form 4 sale | 3,384 | $30k | 1.6% | Plan not stated | SEC |
| Mar 11, 2022 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 693 | $6k | 1.3% | Plan not stated | SEC |
| Mar 2, 2022 | Farwell Wildon | Chief Medical Officer | Form 4 sale | 5,617 | $48k | 7.8% | Plan not stated | SEC |
| Sep 23, 2021 | High Susanna Gatti | Chief Operating Officer | Form 4 sale | 2,451 | $42k | 6.8% | Plan not stated | SEC |
| Sep 21, 2021 | Scalzo Richard William | Officer | Form 4 sale | 859 | $14k | 7.5% | Plan not stated | SEC |
| Sep 21, 2021 | McNeill Jonathan | Officer | Form 4 sale | 1,274 | $20k | 3.5% | Plan not stated | SEC |
| Sep 21, 2021 | Brumm Joshua T | Officer, Director | Form 4 sale | 8,009 | $127k | 7.5% | Plan not stated | SEC |
| Sep 21, 2021 | Beskrovnaya Oxana | Chief Scientific Officer | Form 4 sale | 1,444 | $23k | 7.5% | Plan not stated | SEC |